Hyperfine Overview - Hyperfine's Swoop system is the first FDA-cleared, AI-powered portable MR brain imaging system, targeting a market opportunity exceeding $6 billion[4, 74] - The company's growth strategy is supported by the launch of the next-generation Swoop system and Optive AI software, which enhances image quality for ultra-low field MRI[4] - Hyperfine has secured approximately 200 patents related to its proprietary technology[9] Market and Expansion - The company is targeting expansion across multiple sites of care, including inpatient, outpatient, and community settings, with a total addressable market (TAM) potentially exceeding $16 billion[8] - Hyperfine has an installed base of over 190 Swoop systems globally[52] - The company estimates a potential US Swoop system revenue of $100 million for every 1.5% market penetration[54] Financial Performance - Q3 2025 revenue reached $3.4 million, representing a 27% sequential increase[58] - The effective average selling price (ASP) for the Swoop system in Q3 2025 was approximately $360,000[58] - Cash burn decreased to $5.9 million in Q3 2025, a 27% reduction compared to the previous quarter[59]